NCT00375999已完成2 期
A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
1.Study rationale:There is no standard regimen for the advanced and/or metastatic gastric cancer patients who relapsed after adjuvant chemotherapy or failed to first systemic chemotherapy. 2.Primary Objectives:To evaluate overall response rate according to the Response Evaluation Criteria in Solid Tumors criteria and To investigate time to response 3.Design:single-center, Open label, Phase II study. docetaxel 75mg/m2 administered on day 1 as intravenously combined with intravenous Epirubicin 60mg/m2 given day 2 every 3 weeks. 4.Primary endpoints:
- Efficacy:overall response rate according to the Response Evaluation Criteria in Solid Tumors criteria, time to response, duration of response, and time to treatment failure.
- Safety-Adverse events and laboratory tests, graded according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female outpatients ≥ 18 years,
- •Eastern Cooperative Oncology Group performance status below 1, with histologically confirmed as gastric adenocarcinoma with inoperable and/or metastatic disease.
- •Patients must have at least one target lesion with a minimum lesion size as per the Response Evaluation Criteria in Solid Tumors criteria (at least 1 unidimensional measurable lesion ≥ 20 mm in diameter by conventional CT or MRI scan, or ≥ 10 mm in diameter by spiral CT scan).
- •Creatinine clearance ≥ 60ml/min (estimated creatinine clearance must be calculated at baseline for all patients.)
- •Adequate major organ function : - Hematopoietic function: white blood cell >4,000/mm3 or absolute neutrophil count > 2,000/mm3, Platelet count ≥ 100,000/mm3,- Hepatic function: Bilirubin < 1.5 X upper normal limit, aspartate aminotransferase/alanine aminotransferase levels <2.5 X upper normal limit, alkaline phosphatase < 5 x upper normal limit (except in case of bone metastasis without any liver disease) - Renal function: Creatinine <1 x upper normal limit or creatinine clearance ≥ 60ml/min.
排除标准
- •Patients must not have previously received systemic treatment (cytotoxic chemotherapy or active/passive immunotherapy) for advanced or metastatic disease.
- •Adjuvant or neo-adjuvant treatment for non-metastatic (M0) disease is allowed if completed at least 6 months prior to initiation of study treatment.
- •The following laboratory values: - neutrophils ≤1.5 X 109 /L, platelet count<100 X 109 /L- serum bilirubin ≥ 1.5 X upper normal limit, aspartate aminotransferase
- •, alanine aminotransferase > 2.5 X upper normal limit or > 5 X upper normal limit in the case of liver metastases- Alkaline phosphatase > 2.5 X upper normal limit or 5 X upper normal limit in the case of liver metastases or > 10 X upper normal limit in the case of bone disease.
- •Prior therapy with Taxotere or Epirubicin is excluded.
研究组 & 干预措施
docetaxel and epirubicin
Experimental
salvage docetaxel and epirubicin
干预措施: Docetaxel and epirubicin (Drug)
结局指标
主要结局
Overall Survival
时间窗: One year
次要结局
未报告次要终点
研究者
Jae Yong Cho
Chisf of Medical oncology, Gangnam Severance Hospital
Yonsei University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT02007148International Group of Endovascular Oncology51
已完成
1 期
Dovitinib Plus Docetaxel in Gastric CancerGastric CancerNCT01921673Asan Medical Center14
已完成
2 期
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction AdenocarcinomaEsophageal NeoplasmsGastric CancerNCT00183872University of Southern California40
已完成
2 期
Salvage Docetaxel for Pretreated Urothelial CancerBladder CancerNCT01711112Samsung Medical Center31
已完成
2 期
Docetaxel and Irinotecan in Gastric CancerChemotherapy EffectGastric CancerStomach CancerNCT04770623Menoufia University32